Advertisement

The Emerging Significance of Drug Transporters and Metabolizing Enzymes to Ophthalmic Drug Design

  • Mayssa Attar
  • Jie Shen
Part of the Ophthalmology Research book series (OPHRES)

Summary

Ophthalmic drugs typically achieve less than 10% ocular bioavailability. A drug applied to the surface of the eye may cross ocular–blood barriers, where it may encounter cellular transporters and metabolizing enzymes, before it is distributed to the site of action. Characterization of ocular membrane transporters, enzyme systems and their respective substrate selectivity has provided new insight into the roles these proteins may play in ocular drug delivery and distribution. Altered drug transport and metabolism have been proposed to contribute to a number of ocular disease processes including inflammation, glaucoma, cataract, dry eye and neurodegeneration. With the development of more-sensitive technologies, ocular transport and enzyme systems will continue to be better characterized, and their properties will become an integral consideration in drug design and development.

Introduction

Eye disease can profoundly impact a patient's quality of life. As the population of the...

Keywords

Retinal Pigment Epithelium Ocular Tissue Pseudoxanthoma Elasticum Primary Congenital Glaucoma Diallyl Sulfide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Vision problems in the US: Prevalence of adult vision impairment and age-related eye disease in America. (2002) Prevent Blindness America. www.nei.nih.gov
  2. 2.
    2. Zimmerman TJ, Leader B, Kaufman HE. Advances in ocular pharmacology. Annu Rev Pharmacol Toxicol 1980;20:415–428.PubMedGoogle Scholar
  3. 3.
    3. Lee VHL. Precorneal, corneal and postcorneal factors. In: Mitra, editor. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993. p. 59–81.Google Scholar
  4. 4.
    4. Dey S, Anand BS, Patel J, et al. Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin Biol Ther 2003;3:23–44.PubMedGoogle Scholar
  5. 5.
    5. Ito A, Yamaguchi K, Tomita H, et al. Distribution of rat organic anion transporting polypeptide-E (oatp-E) in the rat eye. Invest Ophthalmol Vis Sci 2003;44:4877–4884.PubMedGoogle Scholar
  6. 6.
    6. Ueda H, Horibe Y, Kim KJ, et al. Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva. Invest Ophthalmol Vis Sci 2000;41:870–876.PubMedGoogle Scholar
  7. 7.
    7. Majumdar S, Tirucherai GS, Pal D, et al. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci 2003;5:E15.PubMedGoogle Scholar
  8. 8.
    8. Majumdar S, Nashed YE, Patel K, et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther 2005;21:463–474.PubMedGoogle Scholar
  9. 9.
    9. Dey S, Gunda S, Mitra AK. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther 2004;311:246–255.PubMedGoogle Scholar
  10. 10.
    10. Dey S, Patel J, Anand BS, et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest Ophthalmol Vis Sci 2003;44:2909–2918.PubMedGoogle Scholar
  11. 11.
    11. Kawazu K, Yamada K, Nakamura M, et al. Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin. Invest Ophthalmol Vis Sci 1999;40:1738–1744.PubMedGoogle Scholar
  12. 12.
    12. Yang JJ, Kim KJ, Lee VH. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm Res 2000;17:533–538.PubMedGoogle Scholar
  13. 13.
    13. Saha P, Yang JJ, Lee VH. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest Ophthalmol Vis Sci 1998;39:1221–1226.PubMedGoogle Scholar
  14. 14.
    14. Budak MT, Alpdogan OS, Zhou M, et al. Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells. J Cell Sci 2005;118:1715–1724.PubMedGoogle Scholar
  15. 15.
    15. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003;3:45–56.PubMedGoogle Scholar
  16. 16.
    16. Ocheltree SM, Keep RF, Shen H, et al. Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes. Pharm Res 2003;20:1364–1372.PubMedGoogle Scholar
  17. 17.
    17. Rajan PD, Kekuda R, Chancy CD, et al. Expression of the extraneuronal monoamine transporter in RPE and neural retina. Curr Eye Res 2000;20:195–204.PubMedGoogle Scholar
  18. 18.
    18. Majumdar S, Macha S, Pal D, et al. Mechanism of ganciclovir uptake by rabbit retina and human retinal pigmented epithelium cell line ARPE-19. Curr Eye Res 2004;29:127–136.PubMedGoogle Scholar
  19. 19.
    19. Greenwood J. Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. J Neuroimmunol 1992;39:123–132.PubMedGoogle Scholar
  20. 20.
    20. Kennedy BG and Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis 2002;8:422–430.PubMedGoogle Scholar
  21. 21.
    21. Aukunuru JV, Sunkara G, Bandi N, et al. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm Res 2001;18:565–572.PubMedGoogle Scholar
  22. 22.
    22. Nakamura K, Fujiki T, Tamura HO. Age, gender and region-specific differences in drug metabolising enzymes in rat ocular tissues. Exp Eye Res 2005;81:710–715.PubMedGoogle Scholar
  23. 23.
    23. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:48–57.PubMedGoogle Scholar
  24. 24.
    24. Wilkinson GR. Pharmacokinetics. In: Hardman AJG, Limbird LE, Goodman Gilman A, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 3–30.Google Scholar
  25. 25.
    25. Shichi H. Microsomal electron transfer system of bovine retinal pigment epithelium. Exp Eye Res 1969;8:60–68.PubMedGoogle Scholar
  26. 26.
    26. McAvoy M, Singh AK, Shichi H. In situ hybridization of Cyp1a1, Cyp1a2 and Ah receptor mRNAs expressed in murine ocular tissues. Exp Eye Res 1996;62:449–452.PubMedGoogle Scholar
  27. 27.
    27. Zhao C and Shichi H. Immunocytochemical study of cytochrome P450 (1A1/1A2) induction in murine ocular tissues. Exp Eye Res 1995;60:143–152.PubMedGoogle Scholar
  28. 28.
    28. Xie Q, Zhang QY, Zhang Y, et al. Induction of mouse CYP2J by pyrazole in the eye, kidney, liver, lung, olfactory mucosa, and small intestine, but not in the heart. Drug Metab Dispos 2000;28:1311–1316.PubMedGoogle Scholar
  29. 29.
    29. Tsao CC, Coulter SJ, Chien A, et al. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J Pharmacol Exp Ther 2001;299:39–47.PubMedGoogle Scholar
  30. 30.
    30. Attar M, Ling KH, Tang-Liu DD, et al. Cytochrome P450 3A expression and activity in the rabbit lacrimal gland: glucocorticoid modulation and the impact on androgen metabolism. Invest Ophthalmol Vis Sci 2005;46:4697–4706.PubMedGoogle Scholar
  31. 31.
    Attar M, Lee VHL, Tang-Liu DS, et al. Characterization of cytochrome P450 1A, 2D and 3A in the rabbit eye. Presented at the AOPT 2003.Google Scholar
  32. 32.
    32. Mastyugin V, Aversa E, Bonazzi A, et al. Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: involvement of a cytochrome P-4504B1 isoform. J Pharmacol Exp Ther 1999;289:1611–1619.PubMedGoogle Scholar
  33. 33.
    33. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet 1997;6:641–647.PubMedGoogle Scholar
  34. 34.
    34. Stoilov I, Akarsu AN, Alozie I, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62:573–584.PubMedGoogle Scholar
  35. 35.
    35. Berkman CE, Park SB, Wrighton SA, et al. In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 1995;50:565–570.PubMedGoogle Scholar
  36. 36.
    36. Huang DY, Furukawa A, Ichikawa Y. Molecular cloning of retinal oxidase/aldehyde oxidase cDNAs from rabbit and mouse livers and functional expression of recombinant mouse retinal oxidase cDNA in Escherichia coli. Arch Biochem Biophys 1999;364:264–272.PubMedGoogle Scholar
  37. 37.
    37. Shimada S, Mishima H, Kitamura S, et al. Nicotinamide N-oxide reductase activity in bovine and rabbit eyes. Invest Ophthalmol Vis Sci 1987;28:1204–1206.PubMedGoogle Scholar
  38. 38.
    38. Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995;23:708–712.PubMedGoogle Scholar
  39. 39.
    39. Lee VH, Chien DS, Sasaki H. Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther 1988;246:871–878.PubMedGoogle Scholar
  40. 40.
    40. Tang-Liu DD, Liu S, Neff J, et al. Disposition of levobunolol after an ophthalmic dose to rabbits. J Pharm Sci 1987;76:780–783.PubMedGoogle Scholar
  41. 41.
    41. Schoenwald RD and Zhu J. The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits. J Ocul Pharmacol Ther 2000;16:481–495.PubMedGoogle Scholar
  42. 42.
    42. Tang-Liu DD, Shackleton M, Richman JB. Ocular metabolism of levobunolol. J Ocul Pharmacol 1988;4:269–278.PubMedGoogle Scholar
  43. 43.
    43. Essner E, Gorrin GM, Griewski RA. Localization of lysosomal enzymes in retinal pigment epithelium of rats with inherited retinal dystrophy. Invest Ophthalmol Vis Sci 1978;17:278–288.PubMedGoogle Scholar
  44. 44.
    44. Lee VH, Chang SC, Oshiro CM, et al. Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. Curr Eye Res 1985;4:1117–1125.PubMedGoogle Scholar
  45. 45.
    45. Stampfli HF and Quon CY. Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res Commun Mol Pathol Pharmacol 1995;88:87–97.PubMedGoogle Scholar
  46. 46.
    46. Lee VH, Iimoto DS, Takemoto KA. Subcellular distribution of esterases in the bovine eye. Curr Eye Res 1982;2:869–876.PubMedGoogle Scholar
  47. 47.
    47. Lee VH, Morimoto KW, Stratford RE Jr. Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability. Biopharm Drug Dispos 1982;3:291–300.PubMedGoogle Scholar
  48. 48.
    48. Putnam ML, Schoenwald RD, Duffel MW, et al. Ocular disposition of aminozolamide in the rabbit eye. Invest Ophthalmol Vis Sci 1987;28:1373–1382.PubMedGoogle Scholar
  49. 49.
    49. Campbell DA, Schoenwald RD, Duffel MW, et al. Characterization of arylamine acetyltransferase in the rabbit eye. Invest Ophthalmol Vis Sci 1991;32:2190–2200.PubMedGoogle Scholar
  50. 50.
    50. Srivastava SK, Singhal SS, Bajpai KK, et al. A group of novel glutathione S-transferase isozymes showing high activity towards 4-hydroxy-2-nonenal are present in bovine ocular tissues. Exp Eye Res 1994;59:151–159.PubMedGoogle Scholar
  51. 51.
    51. Singhal SS, Godley BF, Chandra A, et al. Induction of glutathione S-transferase hGST 5.8 is an early response to oxidative stress in RPE cells. Invest Ophthalmol Vis Sci 1999;40:2652–2659.PubMedGoogle Scholar
  52. 52.
    52. Liu Y and Hu M. P-glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med 2000;38:877–881.PubMedGoogle Scholar
  53. 53.
    53. Lin JH and Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361–390.PubMedGoogle Scholar
  54. 54.
    54. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286:2270–2279.PubMedGoogle Scholar
  55. 55.
    55. Beringer PM and Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother 2005;39:1097–1108.PubMedGoogle Scholar
  56. 56.
    56. Lin JH and Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403–449.PubMedGoogle Scholar
  57. 57.
    57. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611–1613.PubMedGoogle Scholar
  58. 58.
    58. Ishii Y, Nakamura K, Tsutsumi K, et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 2000;40:193–199.PubMedGoogle Scholar
  59. 59.
    59. Novack GD. Excessive beta-blockade with timolol eye drops. JAMA 1996;275:985.PubMedGoogle Scholar
  60. 60.
    60. Putterman GJ, Davidson J, Albert J. Lack of metabolism of timolol by ocular tissues. J Ocul Pharmacol 1985;1:287–296.PubMedGoogle Scholar
  61. 61.
    61. Pai HV, Kommaddi RP, Chinta SJ, et al. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J Biol Chem 2004;279:27383–27389.PubMedGoogle Scholar
  62. 62.
    62. Melki R, Lefort N, Brezin AP, et al. Association of a common coding polymorphism (N453S) of the cytochrome P450 1B1 (CYP1B1) gene with optic disc cupping and visual field alteration in French patients with primary open-angle glaucoma. Mol Vis 2005;11:1012–1017.PubMedGoogle Scholar
  63. 63.
    63. Doshi M, Marcus C, Bejjani BA, et al. Immunolocalization of CYP1B1 in normal, human, fetal and adult eyes. Exp Eye Res 2006;82:24–32.PubMedGoogle Scholar
  64. 64.
    64. Sekine Y, Hommura S, Harada S. Frequency of glutathione-S-transferase 1 gene deletion and its possible correlation with cataract formation. Exp Eye Res 1995;60:159–163.PubMedGoogle Scholar
  65. 65.
    65. Juronen E, Tasa G, Veromann S, et al. Polymorphic glutathione S-transferases as genetic risk factors for senile cortical cataract in Estonians. Invest Ophthalmol Vis Sci 2000;41:2262–2267.PubMedGoogle Scholar
  66. 66.
    66. Duvvuri S, Gandhi MD, Mitra AK. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr Eye Res 2003;27:345–353.PubMedGoogle Scholar
  67. 67.
    67. Majumdar S, Gunda S, Pal D, et al. Functional activity of a monocarboxylate transporter, MCT1, in the human retinal pigmented epithelium cell line, ARPE-19. Mol Pharm. 2005;2:109–117.PubMedGoogle Scholar
  68. 68.
    68. Gandhi MD, Pal D, Mitra AK. Identification and functional characterization of a Na(+)-independent large neutral amino acid transporter (LAT2) on ARPE-19 cells. Int J Pharm 2004;275:189–200.PubMedGoogle Scholar
  69. 69.
    69. Jain-Vakkalagadda B, Dey S, Pal D, et al. Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest Ophthalmol Vis Sci 2003;44:2919–2927.PubMedGoogle Scholar
  70. 70.
    70. Hosoya K, Kondo T, Tomi M, et al. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 2001;18:1669–1676.PubMedGoogle Scholar
  71. 71.
    71. Scott IU, Flynn HW Jr, Miller D, et al. Exogenous endophthalmitis caused by amphotericin B-resistant Paecilomyces lilacinus: treatment options and visual outcomes. Arch Ophthalmol 2001;119:916–919.PubMedGoogle Scholar
  72. 72.
    72. Thomas PA. Fungal infections of the cornea. Eye 2003;17:852–862.PubMedGoogle Scholar
  73. 73.
    73. Arthur RR, Drew RH, Perfect JR. Novel modes of antifungal drug administration. Expert Opin Investig Drugs 2004;13:903–932.PubMedGoogle Scholar
  74. 74.
    74. Toler SM. Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp Biol Med (Maywood) 2004;229:607–615.Google Scholar
  75. 75.
    75. Ohtsuki S, Tomi M, Hata T, et al. Dominant expression of androgen receptors and their functional regulation of organic anion transporter 3 in rat brain capillary endothelial cells; comparison of gene expression between the blood–brain and –retinal barriers. J Cell Physiol 2005;204:896–900.PubMedGoogle Scholar
  76. 76.
    Madhu C, Dinh V, Babusis D, et al. Cytochrome P450 isozyme activities in rabbit ocular tissues. ISSX Proceedings 1998;13.Google Scholar
  77. 77.
    77. Matsumoto K, Kishida K, Manabe R, et al. Induction of cytochrome P-450 in the rabbit eye by phenobarbital, as detected immunohistochemically. Curr Eye Res 1987;6:847–854.PubMedGoogle Scholar
  78. 78.
    78. Tanaka H, Hirayama I, Takehana M, et al. Cytochrome P450 expression in rat ocular tissues and its induction by phenobarbital. Journal of Health Science 2002;48:346–349.Google Scholar
  79. 79.
    79. Nelson KC, Armstrong JS, Moriarty S, et al. Protection of retinal pigment epithelial cells from oxidative damage by oltipraz, a cancer chemopreventive agent. Invest Ophthalmol Vis Sci 2002;43:3550–3554.PubMedGoogle Scholar
  80. 80.
    80. Batrakova EV, Li S, Li Y, et al. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004;21:2226–2233.PubMedGoogle Scholar
  81. 81.
    81. Batrakova EV, Zhang Y, Li Y, et al. Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier. Pharm Res 2004;21:1993–2000.PubMedGoogle Scholar
  82. 82.
    82. Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119–131.PubMedGoogle Scholar
  83. 83.
    83. Carmignani C, Rossi S, Saettone MF, et al. Ophthalmic vehicles containing polymer-solubilized tropicamide: “in vitro/in vivo” evaluation. Drug Dev Ind Pharm 2002;28:101–105.PubMedGoogle Scholar
  84. 84.
    84. Yoshida S, Honda M, Yoshida A, et al. Novel mutation in ABCC6 gene in a Japanese pedigree with pseudoxanthoma elasticum and retinitis pigmentosa. Eye 2005;19:215–217.PubMedGoogle Scholar
  85. 85.
    85. Ringpfeil F, Lebwohl MG, Christiano AM, et al. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 2000;97:6001–6006.PubMedGoogle Scholar
  86. 86.
    86. Nakashima E, Pop-Busui R, Towns R, et al. Regulation of the human taurine transporter by oxidative stress in retinal pigment epithelial cells stably transformed to overexpress aldose reductase. Antioxid Redox Signal 2005;7:1530–1542.PubMedGoogle Scholar
  87. 87.
    87. Layton CJ, Chidlow G, Casson RJ, et al. Monocarboxylate transporter expression remains unchanged during the development of diabetic retinal neuropathy in the rat. Invest Ophthalmol Vis Sci 2005;46:2878–2885.PubMedGoogle Scholar
  88. 88.
    88. Fernandes R, Carvalho AL, Kumagai A, et al. Downregulation of retinal GLUT1 in diabetes by ubiquitinylation. Mol Vis 2004;10:618–628.PubMedGoogle Scholar
  89. 89.
    89. Li Q and Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci 2002;43:3109–3116.PubMedGoogle Scholar
  90. 90.
    90. Shichi H, Gaasterland DE, Jensen NM, et al. Ah locus: genetic differences in susceptibility to cataracts induced by acetaminophen. Science 1978;200:539–541.PubMedGoogle Scholar
  91. 91.
    91. Zhao C and Shichi H. Prevention of acetaminophen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. J Ocul Pharmacol Ther 1998;14:345–355.PubMedGoogle Scholar
  92. 92.
    92. Qian W, Amin RH, Shichi H. Cytotoxic metabolite of acetaminophen, N-acetyl-p-benzoquinone imine, produces cataract in DBA2 mice. J Ocul Pharmacol Ther 1999;15:537–545.PubMedGoogle Scholar
  93. 93.
    93. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990;50:65–78.PubMedGoogle Scholar
  94. 94.
    94. Rao PV, Robison WG Jr, Bettelheim F, et al. Role of small GTP-binding proteins in lovastatin-induced cataracts. Invest Ophthalmol Vis Sci 1997;38:2313–2321.PubMedGoogle Scholar
  95. 95.
    95. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM 2003;96:337–343.PubMedGoogle Scholar
  96. 96.
    96. Boccuzzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991;68:1127–1131.PubMedGoogle Scholar
  97. 97.
    97. Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995;79:996–1002.PubMedGoogle Scholar
  98. 98.
    98. Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002;24:2126–2136.PubMedGoogle Scholar
  99. 99.
    99. Patton WP, Routledge MN, Jones GD, et al. Retinal pigment epithelial cell DNA is damaged by exposure to benzo[a]pyrene, a constituent of cigarette smoke. Exp Eye Res 2002;74:513–522.PubMedGoogle Scholar
  100. 100.
    100. Libby RT, Smith RS, Savinova OV, et al. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science 2003;299:1578–1581.PubMedGoogle Scholar
  101. 101.
    101. Schwartzman ML, Masferrer J, Dunn MW, et al. Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues. Curr Eye Res 1987;6:623–630.PubMedGoogle Scholar
  102. 102.
    102. Schwartzman ML, Davis KL, Nishimura M, et al. The cytochrome P450 metabolic pathway of arachidonic acid in the cornea. Adv Prostaglandin Thromboxane Leukot Res 1991;21A:185–192.PubMedGoogle Scholar
  103. 103.
    103. Schwartzman ML, Balazy M, Masferrer J, et al. 12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea. Proc Natl Acad Sci USA 1987;84:8125–8129.PubMedGoogle Scholar
  104. 104.
    104. Murphy RC, Falck JR, Lumin S, et al. 12(R)-hydroxyeicosatrienoic acid: a vasodilator cytochrome P-450-dependent arachidonate metabolite from the bovine corneal epithelium. J Biol Chem 1988;263:17197–17202.PubMedGoogle Scholar
  105. 105.
    105. Chen P, Guo M, Wygle D, et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 2005;166:615–624.PubMedGoogle Scholar
  106. 106.
    106. Mezentsev A, Mastyugin V, Seta F, et al. Transfection of cytochrome P4504B1 into the cornea increases angiogenic activity of the limbal vessels. J Pharmacol Exp Ther 2005;315:42–50.PubMedGoogle Scholar
  107. 107.
    107. Mieyal PA, Dunn MW, Schwartzman ML. Detection of endogenous 12-hydroxyeicosatrienoic acid in human tear film. Invest Ophthalmol Vis Sci 2001;42:328–332.PubMedGoogle Scholar
  108. 108.
    108. Davis KL, Conners MS, Dunn MW, et al. Induction of corneal epithelial cytochrome P-450 arachidonate metabolism by contact lens wear. Invest Ophthalmol Vis Sci 1992;33:291–297.PubMedGoogle Scholar
  109. 109.
    109. Ashkar S, Mesentsev A, Zhang WX, et al. Retinoic acid induces corneal epithelial CYP4B1 gene expression and stimulates the synthesis of inflammatory 12-hydroxyeicosanoids. J Ocul Pharmacol Ther 2004;20:65–74.PubMedGoogle Scholar
  110. 110.
    110. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277:3–9.PubMedGoogle Scholar
  111. 111.
    111. George RL, Huang W, Naggar HA, et al. Transport of N-acetylaspartate via murine sodium/dicarboxylate cotransporter NaDC3 and expression of this transporter and aspartoacylase II in ocular tissues in mouse. Biochim Biophys Acta 2004;1690:63–69.PubMedGoogle Scholar
  112. 112.
    112. Katragadda S, Talluri RS, Pal D, et al. Identification and characterization of a Na+-dependent neutral amino acid transporter, ASCT1, in rabbit corneal epithelial cell culture and rabbit cornea. Curr Eye Res 2005;30:989–1002.PubMedGoogle Scholar
  113. 113.
    113. Jain-Vakkalagadda B, Pal D, Gunda S, et al. Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol Pharm 2004;1:338–346.PubMedGoogle Scholar
  114. 114.
    114. Maenpaa H, Gegelashvili G, Tahti H. Expression of glutamate transporter subtypes in cultured retinal pigment epithelial and retinoblastoma cells. Curr Eye Res 2004;28:159–165.PubMedGoogle Scholar
  115. 115.
    115. Anand BS and Mitra AK. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm Res 2002;19:1194–1202.PubMedGoogle Scholar
  116. 116.
    116. Basu SK, Haworth IS, Bolger MB, et al. Proton-driven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells. Invest Ophthalmol Vis Sci 1998;39:2365–2373.PubMedGoogle Scholar
  117. 117.
    117. Berger UV and Hediger MA. Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anat Embryol (Berl) 1999;199:439–449.Google Scholar
  118. 118.
    118. Bildin VN, Iserovich P, Fischbarg J, et al. Differential expression of Na:K:2Cl cotransporter, glucose transporter 1, and aquaporin 1 in freshly isolated and cultured bovine corneal tissues. Exp Biol Med (Maywood) 2001;226:919–926.Google Scholar
  119. 119.
    119. Gherzi R, Melioli G, De Luca M, et al. High expression levels of the “erythroid/brain” type glucose transporter (GLUT1) in the basal cells of human eye conjunctiva and oral mucosa reconstituted in culture. Exp Cell Res 1991;195:230–236.PubMedGoogle Scholar
  120. 120.
    120. Takata K, Kasahara T, Kasahara M, et al. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Invest Ophthalmol Vis Sci 1992;33:377–383.PubMedGoogle Scholar
  121. 121.
    121. Takata K, Kasahara T, Kasahara M, et al. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in the ciliary body and iris of the rat eye. Invest Ophthalmol Vis Sci 1991;32:1659–1666.PubMedGoogle Scholar
  122. 122.
    122. Philp NJ, Wang D, Yoon H, et al. Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells. Invest Ophthalmol Vis Sci 2003;44:1716–1721.PubMedGoogle Scholar
  123. 123.
    123. Damm J, Rau T, Maihofner C, et al. Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body. Exp Eye Res 2001;72:611–621.PubMedGoogle Scholar
  124. 124.
    124. Kulkarni PS and Srinivasan BD. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. Prog Clin Biol Res 1989;312:39–52.PubMedGoogle Scholar
  125. 125.
    125. Waltman A and Sears M. Catechol-O-methyl transferase and monoamine oxidase activity in the ocular tissues of albino rabbits. Invest Ophthalmol 1964;3:601.PubMedGoogle Scholar
  126. 126.
    126. Stratford RE Jr and Lee VH. Ocular aminopeptidase activity and distribution in the albino rabbit. Curr Eye Res 1985;4:995–999.PubMedGoogle Scholar
  127. 127.
    127. Stratford RE Jr and Lee VH. Aminopeptidase activity in albino rabbit extraocular tissues relative to the small intestine. J Pharm Sci 1985;74:731–734.PubMedGoogle Scholar
  128. 128.
    128. Azzarolo AM, Bjerrum K, Maves CA, et al. Hypophysectomy-induced regression of female rat lacrimal glands: partial restoration and maintenance by dihydrotestosterone and prolactin. Invest Ophthalmol Vis Sci 1995;36:216–226.PubMedGoogle Scholar
  129. 129.
    129. Mircheff AK, Miller SS, Farber DB, et al. Isolation and provisional identification of plasma membrane populations from cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:863–878.PubMedGoogle Scholar
  130. 130.
    130. Li DW-C, Xiang H, Fass U, et al. Analysis of Expression Patterns of Protein Phosphatase-1 and Phosphatase-2A in Rat and Bovine Lenses. Invest Ophthalmol Vis Sci 2001;42:2603–2609.PubMedGoogle Scholar
  131. 131.
    131. Feeney L. Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies. Invest Ophthalmol Vis Sci 1978;17:583–600.PubMedGoogle Scholar
  132. 132.
    132. Cabral L, Unger W, Boulton M, et al. Regional distribution of lysosomal enzymes in the canine retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:670–676.PubMedGoogle Scholar
  133. 133.
    133. Hayasaka S and Sears ML. Distribution of acid phosphatase, beta-glucuronidase, and lysosomal hyaluronidase in the anterior segment of the rabbit eye. Invest Ophthalmol Vis Sci 1978;17:982–987.PubMedGoogle Scholar
  134. 134.
    134. Robertson MJ, Erwig LP, Liversidge J, et al. Retinal Microenvironment Controls Resident and Infiltrating Macrophage Function during Uveoretinitis. Invest Ophthalmol Vis Sci 2002;43:2250–2257.PubMedGoogle Scholar
  135. 135.
    135. Shichi H, Atlas SA, Nebert DW. Genetically regulated aryl hydrocarbon hydroxylase induction in the eye: possible significance of the drug-metabolizing enzyme system for the retinal pigmented epithelium-choroid. Exp Eye Res 1975;21:557–567.PubMedGoogle Scholar
  136. 136.
    Madhu C, Dinh V, Babusis D, et al. Tissue specific distribution of cytochrome P450 isozymes in the monkey eye. ARVO Proceedings 1999.Google Scholar
  137. 137.
    Madhu C, Dinh V, Babusis D, et al. Expression of cytochrome P450 isoenzymes in dog and human eye. ISSX Proceedings 1999.Google Scholar
  138. 138.
    138. Ikeda H, Ueda M, Ikeda M, et al. Oxysterol 7alpha-hydroxylase (CYP39A1) in the ciliary nonpigmented epithelium of bovine eye. Lab Invest 2003;83:349–355.PubMedGoogle Scholar
  139. 139.
    139. Abraham NG, Lin JH, Dunn MW, et al. Presence of heme oxygenase and NADPH cytochrome P-450 (c) reductase in human corneal epithelium. Invest Ophthalmol Vis Sci 1987;28:1464–1472.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Mayssa Attar
    • 1
  • Jie Shen
    • 1
  1. 1.Department of Pharmacokinetics and Drug MetabolismAllergan Inc.IrvineCA

Personalised recommendations